Current Market Access to Ankylosing Spondylitis Medications

The FDA recently approved Novartis' Cosentyx (secukinumab) for the treatment of non-radiographic axial spondyloarthritis, a form of axial spondyloarthritis (axSpA), in adult patients. Below is a look at market access for ankylosing spondylitis, the more severe form of axSpA in which inflammatory arthritis of the spine is visible on X-ray. For that indication, most medications are covered under both the pharmacy and medical benefit with some limitations. For all of the drugs, more than half of covered lives are under the preferred tier/preferred with prior authorization or step therapy and covered tier/covered with PA/ST under the pharmacy benefit.

NOTES: Under the pharmacy benefit, the numbers of total covered lives under commercial, health exchange, Medicare and Medicaid formularies are 178.3 million, 10.0 million, 46.4 million and 63.1 million, respectively. Under the medical benefit, the numbers of total covered lives under commercial, health exchange, Medicare and Medicaid formularies are 176.2 million, 10.0 million, 48.4 million and 63.1 million, respectively.

SOURCE: Managed Markets Insight & Technology, LLC database as of June 2020.